Imunon (IMNN) vs Lexaria Bioscience (LEXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lexaria Bioscience is the larger company by market cap ($6.6 million vs $6.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNN | LEXX |
|---|---|---|
| Share price | $1.10 | $3.15 |
| Market cap | $6.17M | $6.63M |
| 1-day change | +2.88% | -6.29% |
| EPS (TTM) | $-3.84 | $-5.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.39 | $21.60 |
| 52-week low | $0.96 | $2.77 |
| Distance from 52-week high | -79.59% | -85.42% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1445.45% | +2520.21% |
| Average volume | 155.30K | 62.36K |
| Shares outstanding | 5.61M | 2.11M |
| Employees | 20 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Lexaria Bioscience
LEXX stock →Lexaria Bioscience Corp. operates as a biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
IMNN vs LEXX FAQ
Which is bigger, Imunon or Lexaria Bioscience?
Lexaria Bioscience (LEXX) is larger, with a market capitalization of $6.63M compared with $6.17M for Imunon (IMNN).
Are Imunon and Lexaria Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.